en.Wedoany.com Reported - Neuland Laboratories plans to invest $20 million in building a dedicated 135,000-square-foot process development laboratory and integrated pilot plant at its Genome Valley campus in Hyderabad. The contract development and manufacturing organization (CDMO) aims to deepen collaboration with pharmaceutical and biotech partners from early-stage R&D to commercial production through this facility. The project will be operational in phases, with full completion expected by October 2026. Since it utilizes existing buildings rather than constructing new shells, all investment will go directly into fit-out.
Specializing in process development, the site can accommodate over 500 scientists, making it one of India's largest scale-up research teams. Its core design is to simulate large-scale reactions under small-scale conditions. A spokesperson for Neuland Laboratories told Manufacturing Chemist that this center is not a traditional R&D lab but an advanced process prototyping environment, equipped with specialized tools that allow scientists to replicate specific aspects of large-scale process behavior at a small scale. This helps generate richer development data early in the project, deepen process understanding, and make more accurate scale-up decisions. The company also noted that this model is expected to improve cost efficiency and potentially reduce the need for additional experiments later in development.
The facility integrates a non-GMP pilot plant, enabling scientists to evaluate process performance at a larger scale without relocating or competing for GMP capacity, thereby generating real-time scale-up data while continuously optimizing the process. Neuland explained that this allows multiple experiments to run in parallel, with reaction data digitally recorded and analytical tools supporting faster, evidence-based scientific decisions. Teams can evaluate multiple process routes simultaneously and advance the most promising candidates to pilot-scale validation more efficiently within the same facility. The pilot plant is equipped with 20-250L all-glass reactors, low-temperature capabilities, and multiple filtration systems.
The center will also integrate AI-driven route screening, parallel synthesis, and electronic lab notebooks (ELNs) to support faster decision-making, shorten cycle times, and ensure seamless data continuity.
The centralized analytical department is equipped with comprehensive characterization technologies, featuring specialized areas for process engineering, polymorphism studies, process safety, and advanced flow chemistry. The site also includes five peptide labs and three purification labs. Automated workflows aim to streamline routine tasks, enhance reproducibility, and reduce manual intervention; predictive modeling and data-driven insights guide route selection. By simulating scale-up earlier, Neuland expects to identify failed synthetic routes sooner, eliminating redundant testing and experiments.
The spokesperson added that this integrated model compresses timelines by eliminating handoffs that occur when development and scale-up are conducted at different sites. Traditionally, multi-site operations often lead to handoffs and delays. Consolidating lab development, pilot-scale validation, and process engineering in one location helps reduce these transition points. Combined with parallel experimentation and data-driven decision-making, Neuland told Manufacturing Chemist that this represents a step-change improvement—a more efficient way to deliver scalable, robust processes to clients. While timelines vary by project, the model has the potential to shorten overall development cycles.
The new facility complements Neuland's existing expertise in novel commercial-scale active pharmaceutical ingredient (API) production, forming what the company describes as a highly attractive proposition for both pharmaceutical and biotech partners—meeting current scale and chemistry needs while preparing for commercial production. Neuland stated that few CDMOs can operate in this manner, highlighting it as one of the advantages of working with a true API expert. The company has seen positive responses from global innovators, particularly in areas like complex peptides, as these clients understand the new facility's capabilities. Neuland told Manufacturing Chemist that in multiple discussions, clients recognized the company's ability to address needs they had previously addressed through other partners. Earlier, Neuland reported record quarterly revenue of approximately $83 million.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
